Embecta (EMBC) Expected to Announce Quarterly Earnings on Friday

Key Points

• Embecta is set to release its Q3 2025 earnings on August 8th, with analysts predicting earnings of $0.77 per share and revenue of $278.15 million.
• The company recently announced a quarterly dividend of $0.15, equating to an annualized yield of 5.9%.
• Shares of Embecta are currently trading at $10.16, down 2.8%, and the company has a market cap of $593.75 million.

Embecta (NASDAQ:EMBC - Get Free Report) is projected to post its Q3 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Embecta to post earnings of $0.77 per share and revenue of $278.15 million for the quarter. Embecta has set its FY 2025 guidance at 2.700-2.900 EPS.

Embecta (NASDAQ:EMBC - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.04. Embecta had a negative return on equity of 19.67% and a net margin of 4.89%. The company had revenue of $259.00 million during the quarter, compared to analysts' expectations of $261.77 million. During the same period in the prior year, the company earned $0.67 EPS. Embecta's revenue was down 9.8% compared to the same quarter last year. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Performance

Shares of EMBC traded down $0.04 during trading hours on Monday, reaching $9.92. The stock had a trading volume of 56,253 shares, compared to its average volume of 585,542. The stock has a market capitalization of $579.72 million, a PE ratio of 11.01, a PEG ratio of 0.64 and a beta of 1.08. Embecta has a 12 month low of $9.20 and a 12 month high of $21.48. The company's 50-day moving average is $10.27 and its two-hundred day moving average is $12.58.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EMBC. Wall Street Zen raised Embecta from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. BTIG Research set a $25.00 price target on Embecta and gave the stock a "buy" rating in a research note on Friday, May 23rd. Finally, Mizuho lowered their price objective on Embecta from $13.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday, July 16th.

Insider Buying and Selling at Embecta

In related news, Director David F. Melcher bought 10,000 shares of the company's stock in a transaction dated Friday, May 23rd. The shares were bought at an average price of $10.60 per share, for a total transaction of $106,000.00. Following the completion of the acquisition, the director directly owned 86,681 shares of the company's stock, valued at $918,818.60. This trade represents a 13.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.42% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada grew its holdings in shares of Embecta by 38.3% in the first quarter. Royal Bank of Canada now owns 18,201 shares of the company's stock valued at $232,000 after acquiring an additional 5,036 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company's stock valued at $629,000 after acquiring an additional 1,159 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Embecta by 224.0% in the first quarter. Jane Street Group LLC now owns 132,688 shares of the company's stock valued at $1,692,000 after acquiring an additional 91,729 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Embecta by 4.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company's stock valued at $2,195,000 after acquiring an additional 7,894 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Embecta by 3.7% in the first quarter. AQR Capital Management LLC now owns 225,641 shares of the company's stock valued at $2,738,000 after acquiring an additional 8,109 shares in the last quarter. Institutional investors own 93.83% of the company's stock.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.